Key Takeaway: The article discusses the investigational drug CT1812 by Cognition Therapeutics, focusing on its potential impact on tau, amyloid, and neurodegeneration. However, it primarily serves as a disclaimer regarding third-party website content, lacking detailed information about the drug's effects or clinical findings.
Price reaction · baseline $0.4129 (2025-04-02 close) · hit pre-market · clean, no other CGTX news in the window
day 0 close
-6.5%
day 1
-14.2%
day 3 · peak
-22.3%
Market Sentiment Analysis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
8.3%
average across 6 past catalysts
Cash runway
~33 mo
Minimal dilution risk
Lead asset
Oxytocin
Phase 2 · Oxidative Stress
Full Press Release Details
You are now leaving the Cognition Therapeutics website
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.